Trial Profile

A retrospective study assessing chronic immune thrombocytopenia treatment outcomes in patients who switched from romiplostim or eltrombopag (ROMI/ELT) to Avatrombopag

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 10 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Dec 2024 According to sobi media release, Post-hoc analysis data from this study will be presented at the 66th Annual Meeting of the American Society of Hematology (ASH) in San Diego, CA (USA) from the 7th - 10th of December 2024.
13 Dec 2022 Results assessing the length of therapy (LOT) and persistence (PER) of treatment with an FDA-approved TPO-RA (avatrombopag (AVA), eltrombopag (ELT) or romiplostim (ROMI) in adult ITP patients in the US, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
01 May 2022 Results published in the British Journal of Haematology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com